- CDK4/6 inhibitors push the limits of hormone therapy for breast cancer2019 | First Faculty of Medicine
- CDK4/6 inhibitors in adjuvant therapy of breast cancer2023 | First Faculty of Medicine
- Palbociclib as one of the CDK4/6 inhibitors is of undisputed importance to women with advanced HR+/HER2- breast cancer2019 | Faculty of Medicine in Pilsen
- Inhibitory CDK4/6 mění léčebnou praxi u pokročilého karcinomu prsu2017 | First Faculty of Medicine
- Palbociclib in the treatment of metastatic breast cancer2021 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Ribociclib2018 | First Faculty of Medicine
- Hormonální rezistence u karcinomu prsu a terapie CDK4/6 inhibitory - kazuistika pacientky se sekundární hormonální rezistencí na terapii abemaciclib s fulvestrantem2022 | First Faculty of Medicine
- Cílená léčba inhibitory CDK4/6 v kombinaci s hormonální terapií v první linii léčby metastatického karcinomu prsu u pacientky s generalizací do skeletu sedm let od ukončení adjuvantní terapie2022 | First Faculty of Medicine
- Léčba ribociklibem v 1. linii de novo metastatického HR+/HER2 - karcinomu prsu2020 | First Faculty of Medicine
- Cyclin-dependent kinases - a suitable target in metastatic breast cancer2021 | First Faculty of Medicine
- Successful treatment of metastatic breast tumor using ribociclib in combination with hormonal therapy – case report2023 | Faculty of Medicine in Hradec Králové